ACRS ▼ -18.4% - Aclaris Therapeutics, Inc.
$ACRS Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis - The ADMIRATION Trial Did Not Achieve its Primary Endpoint
16-NOV-2026 05:18 AM ET
Share this post
More filings for $ACRS
ACRS ▼ -6.0% - Aclaris Therapeutics, Inc.Nov 16, 2026ACRS ▼ -6.0% - Aclaris Therapeutics, Inc.Nov 16, 2026ACRS ▲ +1.8% - Aclaris Therapeutics, Inc.Nov 12, 2026ACRS ▲ +3.8% - Aclaris Therapeutics, Inc.Nov 5, 2026ACRS ▼ -3.4% - Aclaris Therapeutics, Inc.Oct 27, 2026ACRS ▼ -4.0% - Aclaris Therapeutics, Inc.Oct 27, 2026
View full $ACRS filing history →💬 Comments
Loading comments…
Leave a comment
